Copyright
©The Author(s) 2022.
World J Transplant. Nov 18, 2022; 12(11): 331-346
Published online Nov 18, 2022. doi: 10.5500/wjt.v12.i11.331
Published online Nov 18, 2022. doi: 10.5500/wjt.v12.i11.331
Table 2 Summary of case reports assessing immune checkpoint inhibitors as a downstaging and/or bridging therapy prior to liver transplantation in patients with hepatocellular carcinoma
Sex | Age, yr | Underlying liver disease | ICI | Cycles (d) | Washout period | Post-LT outcome |
M | 66 | ALD | Nivolumab | 34 | 105 | No rejection |
M | 65 | HCV | Nivolumab | 44 | 8 | Fatal rejection |
M | 39 | HBV | Toripalimab | 10 | 93 | Fatal rejection |
M | 69 | None | Nivolumab | 21 | 18 | No rejection |
F | 56 | HCV | Nivolumab | 8 | 22 | No rejection |
M | 58 | HBV | Nivolumab | 32 | 1 | No rejection |
M | 63 | HCV | Nivolumab | 4 | 2 | No rejection |
M | 30 | HBV | Nivolumab | 25 | 22 | Mild rejection1 |
M | 63 | HBV | Nivolumab | 4 | 13 | No rejection |
M | 66 | HBV | Nivolumab | 9 | 253 | No rejection |
F | 55 | HBV | Nivolumab | 12 | 7 | No rejection |
F | 53 | NASH | Nivolumab | 2 | 30 | No rejection |
M | 61 | HBV | Durvalumab | NA | > 90 | No rejection |
M | 53 ± 12.1 | NA | Camrelizumab and/or Pembrolizumab | 3 ± 2 | 870 on average | 1 rejection in the cohort1 |
- Citation: Ouranos K, Chatziioannou A, Goulis I, Sinakos E. Role of immunotherapy in downsizing hepatocellular carcinoma prior to liver transplantation. World J Transplant 2022; 12(11): 331-346
- URL: https://www.wjgnet.com/2220-3230/full/v12/i11/331.htm
- DOI: https://dx.doi.org/10.5500/wjt.v12.i11.331